

ASX/Media Release

Sun Biomedical's Technology Recognised in Leading Peer Review Publication

Melbourne and Perth, Australia, 29 October 2015: Sun Biomedical Limited (ASX: SBN) today announced the publication of a peer review article highlighting the broad commercial applicability of the company's patented assay technology. The article is co-authored by Chief Scientific Advisor, Associate Professor Kevin Pflieger and refers to Dimerix (Sun Biomedical).

The article published in the *Annual Review of Pharmacology and Toxicology 2016*. It describes the clinical importance of understanding GPCR heteromers in a pharmacological setting, and outlines the most important technologies currently used in research in this area. The Receptor-Heteromer Investigation Technology (Receptor-HIT) owned by Sun Biomedical (Dimerix) is described with reference to a range of reporter systems and reagents with which it can be applied, and which are now widely available commercially.

Sun Biomedical Executive Chairman, Dr James Williams said, "The publication of this high impact review article highlights the pharmacology of this important class of drug targets and the broad commercial application of our proprietary drug discovery platform across multiple research methods currently in widespread use by the pharmaceutical and biotechnology industries."

The article abstract can be found at:

<http://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-011613-135952>

About the Receptor HIT Assay

The Receptor-Heteromer Investigation Technology (Receptor-HIT) was originally invented in the Laboratory for Molecular Endocrinology at the Harry Perkins Institute of Medical Research (formerly Western Australian Institute for Medical Research, WAIMR) and The University of Western Australia (UWA). This assay enables the identification of pairs of receptors that functionally interact when ligands, small molecule drugs, peptides or antibodies, bind to them. The technology was spun out from the University into Dimerix Bioscience Pty Ltd in 2006. This technology has since been used by the company to assist in understanding and developing receptor-based therapeutic programs, both for Dimerix and other pharmaceutical companies, with the goal of increasing efficacy and decreasing side effect profiles through elucidating the therapeutic relevance of heteromer interactions. The technology is protected by granted or issued patents in major jurisdictions including the USA, Europe and Australia.

Associate Professor Kevin Pflieger

Kevin is a National Health and Medical Research Council (NHMRC) RD Wright Biomedical Research Fellow (Level 2) and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research (formerly Western Australian Institute for Medical Research, WAIMR) and The University of Western Australia (UWA). Kevin was Chief Scientific Officer of Dimerix Bioscience from 2008 until Dimerix became a public company in June 2014 where he continues in the role of Chief Scientific Advisor. He was awarded his MA and PhD from Cambridge and Edinburgh Universities and is a former NHMRC Peter Doherty Research Fellow and Australian Research Council (ARC) Future Fellow. He was awarded Western Australian Young Scientist of the Year 2009, NHMRC 10 of the Best Research Projects 2010, Australian Museum Eureka Prize for Emerging Leader in Science 2011, The Endocrine Society Early Investigators Award 2012, Western Australia Young Tall Poppy Science Award 2012, Endocrine Society of Australia Mid-Career Research Award 2014, NHMRC Research Excellence Award 2014 and UWA Vice-Chancellor's Mid-Career Research Award 2015.

Kevin is one of the world's foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G protein-coupled receptors (GPCRs), one of the most important classes of drug targets. In his position at the Perkins and UWA, he co-invented patented technology enabling study of receptor interactions. This intellectual property was assigned to Dimerix, and subsequently acquired by Sun Biomedical Limited.

For more information please contact:

Dr James Williams
Executive Chairman
Tel: +61 409 050 519

About Dimerix Bioscience Limited

Sun Biomedical Limited's wholly owned subsidiary Dimerix Bioscience Limited is a clinical-stage pharmaceutical company committed to discovering and developing new therapeutic paradigms identified using its proprietary screening assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT). This assay enables the identification of pairs of receptors that function in a joint manner (interact) when ligands, small molecule drugs, peptides or antibodies, bind to them. The Receptor-HIT technology was used to identify DMX-200 and an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease. In addition to its own therapeutic programs, the company also earns revenue by providing this technology to global pharmaceutical firms. Sun Biomedical acquired DMX-200, and the Receptor-HIT technology, through its acquisition of Dimerix Bioscience Limited, which completed in early July 2015.